{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "for-development", "type": "clause", "offset": [23, 38]}, {"key": "liquitime-technology", "type": "definition", "offset": [44, 64]}, {"key": "in-accordance-with", "type": "definition", "offset": [79, 97]}, {"key": "section-41", "type": "clause", "offset": [98, 109]}], "size": 5, "samples": [{"hash": "4rXMuZ1nWO5", "uri": "/contracts/4rXMuZ1nWO5#selected-compound", "label": "License and Development Agreement (Cerecor Inc.)", "score": 29.3559206023, "published": true}, {"hash": "4OIrP1kulad", "uri": "/contracts/4OIrP1kulad#selected-compound", "label": "License and Development Agreement (Cerecor Inc.)", "score": 29.3559206023, "published": true}, {"hash": "bew7NpLCKwj", "uri": "/contracts/bew7NpLCKwj#selected-compound", "label": "License and Development Agreement (Avadel Pharmaceuticals PLC)", "score": 29.3258042437, "published": true}], "snippet": "means the API selected for development in a LiquiTime Technology-based Product in accordance with Section 4.1.", "hash": "70baf16a45a26586d45c6ada0c825d0e", "id": 1}, {"snippet_links": [{"key": "as-specified", "type": "clause", "offset": [135, 147]}, {"key": "from-time-to-time", "type": "clause", "offset": [148, 165]}, {"key": "a-sub", "type": "clause", "offset": [169, 174]}, {"key": "a-separate", "type": "definition", "offset": [199, 209]}, {"key": "prepared-for", "type": "definition", "offset": [275, 287]}, {"key": "signed-by", "type": "clause", "offset": [350, 359]}, {"key": "authorized-employee", "type": "definition", "offset": [363, 382]}, {"key": "of-each-party", "type": "clause", "offset": [383, 396]}], "size": 4, "samples": [{"hash": "dxmJffM4m4c", "uri": "/contracts/dxmJffM4m4c#selected-compound", "label": "Development and Production Agreement", "score": 31.340862423, "published": true}, {"hash": "dfluq6tMn9Q", "uri": "/contracts/dfluq6tMn9Q#selected-compound", "label": "Development and Production Agreement (Targacept Inc)", "score": 21.0, "published": true}, {"hash": "8X1H5q2CUUI", "uri": "/contracts/8X1H5q2CUUI#selected-compound", "label": "Development and Production Agreement (Targacept Inc)", "score": 21.0, "published": true}], "snippet": "means a COMPOUND (or finished dosage form(s) of a COMPOUND) for which TARGACEPT engages SIEGFRIED to perform DEVELOPMENT or PRODUCTION as specified from time to time in a sub-appendix to Appendix A. A separate sequentially numbered sub-appendix (\u2587-\u2587, \u2587-\u2587 and so on) shall be prepared for each SELECTED COMPOUND, which sub-appendix shall be dated and signed by an authorized employee of each party, attached hereto and thereupon become a part hereof.", "hash": "7b42b044c68c80df893f4b619d9101f4", "id": 2}, {"snippet_links": [], "size": 3, "samples": [{"hash": "9A3bu6MzCSE", "uri": "/contracts/9A3bu6MzCSE#selected-compound", "label": "Research Collaboration Agreement (Aptinyx Inc.)", "score": 29.3887748118, "published": true}, {"hash": "iAq6FNplJKf", "uri": "/contracts/iAq6FNplJKf#selected-compound", "label": "Research Collaboration Agreement (Aptinyx Inc.)", "score": 29.2409308693, "published": true}, {"hash": "bmcVRse57OI", "uri": "https://ir.aptinyx.com/static-files/051a21a2-f3f2-4443-92a0-33b04459ae70", "label": "ir.aptinyx.com", "score": 8.1704312115, "published": false}], "snippet": "means any SpinCo Selected Compound or any Company Selected Compound, as applicable.", "hash": "54cfb23518cd1a6986843eb4ff0b57c8", "id": 3}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [81, 96]}, {"key": "section-31", "type": "clause", "offset": [140, 151]}, {"key": "exclusive-options", "type": "clause", "offset": [153, 170]}, {"key": "bispecific-antibody", "type": "definition", "offset": [255, 274]}, {"key": "multispecific-antibody", "type": "definition", "offset": [276, 298]}, {"key": "the-parties", "type": "clause", "offset": [331, 342]}, {"key": "selected-compounds", "type": "clause", "offset": [351, 369]}, {"key": "mutual-written-agreement", "type": "clause", "offset": [375, 399]}], "size": 3, "samples": [{"hash": "jgaQI0dDqEh", "uri": "/contracts/jgaQI0dDqEh#selected-compound", "label": "Collaboration, Option and License Agreement (iBio, Inc.)", "score": 32.65229295, "published": true}, {"hash": "2m4U9gIVFkZ", "uri": "http://pdf.secdatabase.com/798/0001104659-21-110011.pdf", "label": "pdf.secdatabase.com", "score": 10.8726899384, "published": false}, {"hash": "2PgVB3fdCCQ", "uri": "https://ir.ibioinc.com/sec-filings/content/0001104659-21-110011/0001104659-21-110011.pdf", "label": "ir.ibioinc.com", "score": 10.826146475, "published": false}], "snippet": "means, for each Collaboration (and Program), each of the two (2) Lead Candidates with respect to which iBio exercises an Option pursuant to Section 3.1 (Exclusive Options), including any derivative, fragment, or variant of such Lead Candidates (including bispecific antibody, multispecific antibody, and antibody drug conjugates). The Parties may add Selected Compounds upon mutual written agreement.", "hash": "a8655b321eb3b4cfb47e277f33a75487", "id": 4}, {"snippet_links": [{"key": "licensed-compound", "type": "definition", "offset": [8, 25]}, {"key": "notice-given", "type": "clause", "offset": [66, 78]}, {"key": "at-any-time", "type": "clause", "offset": [86, 97]}, {"key": "development-term", "type": "clause", "offset": [123, 139]}, {"key": "section-32", "type": "clause", "offset": [155, 166]}, {"key": "clinical-development", "type": "clause", "offset": [201, 221]}, {"key": "pursuant-to-section", "type": "clause", "offset": [222, 241]}], "size": 3, "samples": [{"hash": "kTLHE0epyOu", "uri": "/contracts/kTLHE0epyOu#selected-compound", "label": "Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "aWgb3DDt35L", "uri": "/contracts/aWgb3DDt35L#selected-compound", "label": "Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means a Licensed Compound which MRE, by written ----------------- notice given to DTI at any time during the Discovery and Development Term (as defined in Section 3.2), has selected as a candidate for clinical development pursuant to Section 3.2.", "hash": "c6f021fed0fb6cc8b5f180318b5b2f5e", "id": 5}, {"snippet_links": [{"key": "proprietary-compound", "type": "definition", "offset": [45, 65]}, {"key": "either-party", "type": "definition", "offset": [69, 81]}, {"key": "the-research-program", "type": "clause", "offset": [108, 128]}, {"key": "rna-target", "type": "definition", "offset": [140, 150]}, {"key": "threshold-activity", "type": "definition", "offset": [175, 193]}, {"key": "structural-information", "type": "clause", "offset": [265, 287]}, {"key": "pursuant-to-section", "type": "clause", "offset": [296, 315]}], "size": 2, "samples": [{"hash": "6qwRnBcm8U4", "uri": "/contracts/6qwRnBcm8U4#selected-compound", "label": "Research Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "dmGJ4B3wML8", "uri": "https://ir.ionispharma.com/static-files/76e56b34-25d9-4c9a-aae7-8b5233c1aabb", "label": "ir.ionispharma.com", "score": 9.9650924025, "published": false}], "snippet": "means any Agouron Screening Compound, or any proprietary compound of either Party supplied for screening in the Research Program against an RNA Target, and determined to have Threshold Activity against an RNA Target, and for which compound Agouron has provided the structural information to Ibis pursuant to Section 3.1.3.", "hash": "aa91f5229bbb8d0c217377d63235ebc0", "id": 6}, {"snippet_links": [{"key": "active-compound", "type": "definition", "offset": [10, 25]}, {"key": "section-31", "type": "clause", "offset": [113, 124]}, {"key": "for-clarity", "type": "clause", "offset": [126, 137]}, {"key": "development-compounds", "type": "clause", "offset": [143, 164]}, {"key": "selected-compounds", "type": "clause", "offset": [176, 194]}], "size": 2, "samples": [{"hash": "eIxfgZeR5YJ", "uri": "/contracts/eIxfgZeR5YJ#selected-compound", "label": "Collaboration and License Agreement (Arena Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "7brYelzcC3Q", "uri": "https://invest.arenapharm.com/static-files/ec99a883-cff1-4291-90d2-9d6fcae6e71e", "label": "invest.arenapharm.com", "score": 9.0533880903, "published": false}], "snippet": "means any Active Compound, up to a maximum of ***** **** compounds, that has been selected by J&J as provided in Section 3.1. For clarity, all Development Compounds are deemed Selected Compounds.", "hash": "e9318975fbb006b56e801d0078381292", "id": 7}, {"snippet_links": [{"key": "in-respect-of", "type": "clause", "offset": [29, 42]}], "size": 2, "samples": [{"hash": "1ZNB6fLnX3D", "uri": "/contracts/1ZNB6fLnX3D#selected-compound", "label": "Screening Agreement (Anadys Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "12fOmJyYSfL", "uri": "/contracts/12fOmJyYSfL#selected-compound", "label": "Screening Agreement (Anadys Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means an Evaluation Compound in respect of which Anadys has given Cerylid a Selected Compound Notice;", "hash": "c625e614a57f5f3aabafc1ceadb7a971", "id": 8}, {"snippet_links": [{"key": "active-compounds", "type": "clause", "offset": [18, 34]}, {"key": "the-applicable", "type": "clause", "offset": [143, 157]}, {"key": "in-accordance-with", "type": "definition", "offset": [191, 209]}, {"key": "pursuant-to-section", "type": "clause", "offset": [260, 279]}, {"key": "the-agreement", "type": "clause", "offset": [290, 303]}], "size": 2, "samples": [{"hash": "hY4GwfTQfsU", "uri": "/contracts/hY4GwfTQfsU#selected-compound", "label": "Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "e9ylXQju5Nm", "uri": "/contracts/e9ylXQju5Nm#selected-compound", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means any and all Active Compounds and/or Improved Active Compounds which have demonstrated bioactivity in secondary functional assays against the applicable Target as determined by Schering in accordance with Section 2.7, and which are designated by Schering pursuant to Section 2.7(a) of the Agreement.", "hash": "1be2d4e83122f448d4aed68372d3e83a", "id": 9}, {"snippet_links": [{"key": "active-compounds", "type": "clause", "offset": [18, 34]}, {"key": "the-applicable", "type": "clause", "offset": [143, 157]}, {"key": "in-accordance-with", "type": "definition", "offset": [186, 204]}, {"key": "pursuant-to-section", "type": "clause", "offset": [250, 269]}, {"key": "the-agreement", "type": "clause", "offset": [280, 293]}], "size": 2, "samples": [{"hash": "8PJE1SfoYnb", "uri": "/contracts/8PJE1SfoYnb#selected-compound", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "236ZVlBhHXt", "uri": "/contracts/236ZVlBhHXt#selected-compound", "label": "Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means any and all Active Compounds and/or Improved Active Compounds which have demonstrated bioactivity in secondary functional assays against the applicable Target as determined by SPL in accordance with Section 2.7, and which are designated by SPL pursuant to Section 2.7(a) of the Agreement.", "hash": "96fc4333cd9efc6b4aab314ca5327713", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIac2VsZWN0ZWQtY29tcG91bmQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Selected Compound", "size": 40, "snippet": "means the API selected for development in a LiquiTime Technology-based Product in accordance with Section 4.1.", "id": "selected-compound", "examples": ["For each Compound and <strong>Selected Compound</strong> evaluated by Firmenich under this Agreement, Firmenich will use commercially reasonable precautions in the evaluation of such compound including, without limitation, not exceeding concentration and exposure limits provided by Senomyx and following other guidelines provided by Senomyx with respect to any tasting by humans.", "In addition, with respect to payments to Senomyx for sales of <strong>Selected Compound</strong> [\u2026***\u2026], Firmenich (or its respective Affiliate) will furnish to Senomyx a royalty statement to permit confirmation of the accuracy of the royalty payment made, which includes [\u2026***\u2026].", "In the event that Senomyx does not receive such written notice from Firmenich within the timeframe set forth above or in the event that Firmenich determines that such Compound is not Commercially Viable, then notwithstanding any other provision of this Agreement to the contrary, such Compound will thereafter not be considered a <strong>Selected Compound</strong> under the Agreement.", "Within [\u2026***\u2026] of the selection of a <strong>Selected Compound</strong>, Firmenich will prepare a plan for product development (\u201cProduct Development Plan\u201d) for Products incorporating such <strong>Selected Compound</strong> for review by the Steering Committee (the \u201cProduct Development Plan\u201d), which will be incorporated into the minutes of the Steering Committee; however, Firmenich shall have sole discretion to determine the Product Development Plan.", "The Commercialization Plans for each <strong>Selected Compound</strong> will be attached to the minutes of the applicable Steering Committee meeting.", "For the avoidance of doubt, if PEPSICO selects multiple Collaboration Compounds within any of the five Minimum Annual Royalty Categories, the Royalty Shortfall shall be due for that category and not for each <strong>Selected Compound</strong> within that category.", "SENOMYX will provide PEPSICO with such results for any <strong>Selected Compounds</strong> both during and following the Collaborative R &amp; D Period, for so long as such Collaboration Compound remains a <strong>Selected Compound</strong>.", "MRE shall direct the Research and Development, if any, of each <strong>Selected Compound</strong> in any manner, and with such commitment of financial and other resources as it in its sole discretion deems appropriate.", "By way of example, patent applications directed to composition of matter of a <strong>Selected Compound</strong>, use of a <strong>Selected Compound</strong> in comestible compositions, and methods of making a <strong>Selected Compound</strong> would be subject to a reimbursement obligation.", "If PEPSICO timely selects a Collaboration Compound by written notice to SENOMYX no later than the Selection Date for such Collaboration Compound, such Collaboration Compound will thereafter be deemed a \u201c<strong>Selected Compound</strong>\u201d and PEPSICO and its Affiliates shall have the license rights to such <strong>Selected Compound</strong> set forth in Section 9."], "related": [["lead-compound", "Lead Compound", "Lead Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"], ["product-candidate", "Product Candidate", "Product Candidate"]], "related_snippets": [], "updated": "2025-07-07T00:16:46+00:00"}, "json": true, "cursor": ""}}